



**Nectar Lifesciences UK Limited**  
**Annual Report and Unaudited Financial Statements**  
**For the year ended 31 March 2017**

---

Company Registration No. 07547409 (England and Wales)

---

## Nectar Lifesciences UK Limited

### Company Information

---

<b>Directors</b>	Dr D Dua Nectar Lifesciences Limited	(Appointed 1 April 2016)
<b>Company number</b>	07547409	
<b>Registered office</b>	Devonshire House 80 Goswell Road London EC1M 7AD	
<b>Accountants</b>	Kingston Smith LLP Surrey House 35-44 High Street Redhill Surrey RH1 1RH	

---

---

Nectar Lifesciences UK Limited

Directors' Report

For the year ended 31 March 2017

---

The directors present their annual report and financial statements for the year ended 31 March 2017.

**Principal activities**

The company is dormant and has not traded during the year.

**Directors**

The directors who held office during the year and up to the date of signature of the financial statements were as follows:

Dr D Dua	(Appointed 1 April 2016)
Mr Aryan Goyal	(Resigned 1 April 2016)
Nectar Lifesciences Limited	

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies exemption.

On behalf of the board



Dr D Dua  
Director

Nectar Lifesciences UK Limited

Profit and Loss Account

For the year ended 31 March 2017

---

	2017	2016
	£	£
Profit before taxation	-	-
Taxation	-	-
Profit for the financial year	-	-
Total comprehensive income for the year	-	-

---

# Nectar Lifesciences UK Limited

## Balance Sheet

As at 31 March 2017

	Notes	2017 £	£	2016 £	£
<b>Current assets</b>					
Debtors	2	1		1	
<b>Creditors: amounts falling due within one year</b>					
Net current assets			1		1
<b>Capital and reserves</b>					
Called up share capital	3		1		1


For the financial year ended 31 March 2017 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

### Directors' responsibilities:

- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476;
- The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime.

The financial statements were approved by the board of directors and authorised for issue on ..... and he signed on its behalf by:



Dr D Dua  
Director

Company Registration No. 07547409

## Nectar Lifesciences UK Limited

### Notes to the Financial Statements

For the year ended 31 March 2017

#### 1 Accounting policies

##### Company information

Nectar Lifesciences UK Limited is a private company limited by shares incorporated in England and Wales. The registered office is Devonshire House, 60 Goswell Road, London, EC1M 7AD.

##### 1.1 Accounting convention

The financial statements are prepared under the historical cost convention.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest pound.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

These financial statements for the year ended 31 March 2017 are the first financial statements of Nectar Lifesciences UK Limited prepared in accordance with FRS 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland. The date of transition to FRS 102 was 1 April 2015. The reported financial position and financial performance for the previous period are not affected by the transition to FRS 102.

##### 1.2 Financial instruments

The company only has financial instruments classified as basic and measured at amortised cost. The company has no financial instruments that are classified as 'other' or financial instruments measured at fair value.

##### 1.3 Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of direct issue costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

#### 2 Debtors

	2017	2016
	£	£
Amounts falling due within one year:		
Amounts due from group undertakings	1	1

#### 3 Called up share capital

	2017	2016
	£	£
Ordinary share capital issued and fully paid		
1 ordinary share of £1	1	1

#### 4 Related party transactions

The company has taken the exemption from disclosing related party transactions with companies under the same control in accordance with FRS 102 - Section 33 'Related Party Disclosures'.

## Nectar Lifesciences UK Limited

### Notes to the Financial Statements (Continued)

For the year ended 31 March 2017

---

#### **5 Parent company**

The parent company is Nectar Lifesciences Limited, a company registered in India, by virtue of its' 100% shareholding in the company. There is no ultimate controlling party of Nectar Lifesciences Limited.

Consolidated group accounts are being prepared by Nectar Lifesciences Limited. These can be obtained from the registered office: Village Saidpura, Tehsil Derabassi, Distt. S.A.S. Nagar (Mohali) Punjab, India.



## **Nectar Lifesciences USA LLC**

Notes to the Financial Statements  
For the year ended March 31, 2017

### **1. Accounting Policies**

#### **1.1. Accounting Conventions**

The financial statements are prepared under the cost convention and in accordance with the financial reporting standard for smaller entities.

### **2. Control**


The immediate controlling party is Nectar Lifesciences Limited, a company registered in India, by virtue of its 100% shareholding in the company. There is no ultimate controlling party of Nectar Lifesciences Limited.

Consolidated group accounts are being prepared by Nectar Lifesciences Limited. These can be obtained from the registered office: Village Saidpura, Tehsil Derabassi, Distt: S.A.S. Nagar (Mohali) Punjab, India.

### **3. Balance Sheet and Profit and Loss Accounts**

Balance Sheet and Profit and Loss Accounts and attached with reports and entries contained there are self explanatory.

For Nectar Lifesciences USA LLC

  
(Saurabh Goyal)  
President




**RAJEEV KAUL, CPA, PC**  
**CERTIFIED PUBLIC ACCOUNTANT**


**NECTAR LIFESCIENCES USA LLC**  
**PROFIT & LOSS ACCOUNT FOR THE YEAR ENDED 31.03.2017**

PARTICULARS	AMOUNT (USD)	PARTICULARS	AMOUNT (USD)
To Opening Stock	\$97,433.28	By Sales	\$1,340,572.00
To Purchases	\$1,302,472.80	By Closing Stock	\$80,740.80
To Freight Charges	\$1,054.00		
To Warehousing Charges	\$1,500.00		
To Professional Charges	\$2,775.00		
To Net Profit	\$18,077.72		
	<u>\$1,421,312.80</u>		<u>\$1,421,312.80</u>

**NECTAR LIFESCIENCES USA LLC**  
**BALANCE SHEET AS ON 31.03.2017**

LIABILITIES	AMOUNT (USD)	ASSETS	AMOUNT (USD)
Share Capital		Current Assets	
Nectar Lifesciences Ltd India	\$51,950.00	Closing Stock	\$80,740.80
Sundry Creditors	\$343,041.92	Bank Balance - Cit Bank USA	\$57,153.73
		Sundry Debtors	\$234,730.00
		Profit & Loss (Loss)	\$22,577.39
		Balance as on 01.04.2016	\$98,455.11
		Less: Profit during the year	<u>\$16,077.72</u>
	<u>\$894,991.92</u>		<u>\$894,991.92</u>

For Nectar Lifesciences USA, LLC  
  
 Saunabh Goyal  
 President

  
**RAJEEV KAUL, CPA PC**  
 303 5TH AVENUE #1007  
 NEW YORK, NY-10016  
 05/31/2017